An observational study in Heart Failure With Reduced Ejection Fraction and HFrEF - Heart Failure With Reduced Ejection Fraction, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Heart Failure by Assiut University — 12 open to participants now, 12 under way, none of them phase 3. Heart Failure · Assiut University.
Among the 23 studies in Heart Failure by Assiut University, this one is the 4th largest by planned enrollment of the 20 observational ones that give a count, is one of 5 that started in 2026, is one of 20 observational ones, reaches primary completion later than 7 of the 11 other live ones, and was the 22nd registered.
6,332 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →12 of the 23 studies in Heart Failure by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University
Ages 18–65
Assiut University
Ages 18+
Assiut University
Ages 18+
Assiut University · Sites in Egypt
Ages 18+
Assiut University
Ages 18+
By country, each count listing its studies:
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 200 across 1,983 observational studies indexed under Heart Failure.
Median enrollment 100 across the 3 interventional studies, 100 across the 20 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,081 studies on the registry; 2,179 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
5 of the studies in Heart Failure by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07277140Assiut UniversityImpact of Iron Deficiency on Arrhythmic Events and Resting ECG Abnormalities in Patients Hospitalized With Heart Failure | 2027-01-01 |
| NCT07821801Assiut UniversityShort-Term Outcomes of HFrEF Patients on Guideline-Directed Medical Therapy | 2027-09-10 |
| NCT07830940Assiut UniversityFinerenone and Cardiac Remodeling in HFpEF | 2027-09-25 |
| NCT07845201Assiut UniversityIntermediate Outcomes of HFrEF Patients on Guideline-Directed Medical Therapy | 2027-09-26 |
| NCT07847112Assiut UniversitySoluble TREM-1 in Diabetes-Associated Cardiovascular Complications | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 23 studies in Heart Failure by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective observational study aims to evaluate intermediate clinical, renal, and functional outcomes in patients with heart failure with reduced ejection fraction treated with contemporary guideline-directed medical therapy over a 6 to 12 month follow-up period.
Guideline-directed medical therapy (GDMT) is the cornerstone of treatment for heart failure with reduced ejection fraction. This observational study will enroll adult patients with chronic HFrEF (LVEF ≤ 40%) who are stable on or planned to initiate GDMT.
Patients will be followed for 6 to 12 months to assess changes in renal function, functional status, quality of life, left ventricular ejection fraction, hospitalization rates, and medication adherence.
Adult patients with chronic heart failure with reduced ejection fraction attending the Cardiovascular Department at Assiut University.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients with heart failure with reduced ejection fraction who are receiving or planned to receive contemporary guideline-directed medical therapy and will be followed for intermediate outcomes.
Change in NYHA functional class
Change in New York Heart Association (NYHA) functional class from baseline to follow-up.
Time frame: Baseline and at 6 to 12 months
Change in KCCQ-12 score
Change in Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) total score from baseline to follow-up (range 0-100, higher scores indicate better health status).
Time frame: From baseline to 6 to 12 months
Change in left ventricular ejection fraction
Change in left ventricular ejection fraction (LVEF) measured by echocardiography from baseline to follow-up.
Time frame: From baseline to 6 to 12 months
Change in estimated glomerular filtration rate
Change in estimated glomerular filtration rate (eGFR) calculated by CKD-EPI equation from baseline to follow-up.
Time frame: From baseline to 6 to 12 months
Rate of heart failure hospitalization
Number of heart failure-related hospital admissions during the follow-up period.
Time frame: From baseline to 6 to 12 months
Proportion of patients on each GDMT component
Proportion of patients prescribed each of the four foundational GDMT drug classes at follow-up.
Time frame: At 6 to 12 months
Medication adherence score
Mean Morisky Medication Adherence Scale-8 (MMAS-8) score (range 0-8, higher scores indicate better adherence).
Time frame: At 6 to 12 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
Of 794 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 99. This study's planned 12 months is below that.
Counting every sponsor, half of 976 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.